Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.

Clicks: 409
ID: 108009
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #6 of 241 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 241 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
Reference Key
zingg2020cefiderocolopen Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zingg, Sandra;Nicoletti, G Jacopo;Kuster, Sabine;Junker, Milena;Widmer, Andreas;Egli, Adrian;Hinic, Vladimira;Sendi, Parham;Battegay, Manuel;Bättig, Veronika;Khanna, Nina;Tschudin-Sutter, Sarah;
Journal Open forum infectious diseases
Year 2020
DOI
10.1093/ofid/ofaa185
URL
Keywords
review case series carbapenemase cefiderocol drug-resistant gram-negatives

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.